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Results: At time of transplantation, ADV-CD4Tvis were detectable in 30/31 patients
(intervention group), CMV-CD4Tvis and HSV-CD4Tvis only in 12/31. No significant
ADV- or HSV-DNAemia was found; only two patients showed transient CMV-DNAemia
based on CMV-reactivation. Five primary CMV-infections with seroconversion and boost
of CMV-CD4Tvis were observed without significant CMV-DNAemia. The mean level of
ADV-CD4Tvis was 1.63(SD1.25), 2.03(SD1.8), 2.18(SD2.51) and 1.97 cells/µl(SD1.34)
1,6,12 and 24 months after KTx. In case of CD4Tvis <2cells/µl 125 dose reductions of
immunosuppressants (96% based on ADV-CD4Tvis) were performed in 28/31 children
with a median of 4 Tvis-based dose reductions (range 0-10) per patient. 48% of these were
carried out in the first six months.
Conclusions: Under the intensified immunosuppression during the initial postKTx period low ADV-CD4Tvis levels were observed with subsequent increase after
dose reduction of the immunosuppression. ADV-CD4Tvis are most suitable for immune
monitoring because of their high prevalence (even in children) and stability combined with
absence of ADV-DNAemia. Routine monitoring of ADV-CD4Tvis is recommendable
especially in the first post-KTx year to prematurely identify overimmunosuppression.
Funding: Government Support - Non-U.S.
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Methods: We enrolled 144 KT recipients with stable graft function between 1989 and
2018. Differentiation and expansion of Tregs were studied by flow cytometry to compare
the Tregs subpopulations. Tregs were defined as CD4+CD25highCD127low/-FoxP3+ cells.
Results: Among the 144 patients, 75 patients (65.8%) were males and mean
follow-up period was 144.3 ± 111.5 months. All patients received calcineurin inhibitors
as maintenance immunosuppressants. Patients with follow-up period more than 144.3
months tended to have more gating Tregs numbers than that in shorter follow-up period
(92.3 ± 142.4 vs. 50.1 ± 76.4, p = 0.061, respectively). There were no significant
differences in Tregs subpopulations between patients with serum creatinine more than
1.5 md/dL and patients with serum creatinine less than 1.5 mg/dL. In terms of the number
of Tregs, when the trough level of tacrolimus was at an appropriate level, the number of
Tregs tended to be higher than that of Tregs when the trough level of tacrolimus was low
or high, and the organ function of the transplant was also stable.
Conclusions: Tregs counts may be associated with transplant outcomes considering
that there is a relationship between these cells and kidney graft function.
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Regulatory T Cells, BK Virus Infection, and Long-Term Outcomes in
Kidney Transplant Recipients
Yasar Caliskan,1 Bayram Kiran,2 Cigdem Kekik,3 Halil Yazici,3 Hayriye Senturk
Ciftci,3 Ahmet B. Dirim,3 Safak Mirioglu,3 Ozgur A. Oto,3 Henry B. Randall,1
Fatma Savran Oguz,3 Aydin Turkmen,3 Krista L. Lentine.1 1Saint Louis
University School of Medicine, Saint Louis, MO; 2Kastamonu Universitesi,
Kastamonu, Turkey; 3Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul,
Turkey.
Background: Regulatory T cells (Tregs) may inhibit pathogen-specific immunity in
infectious disorders. We monitored Treg levels during BK virus (BKV) viremia/viruria,
examined pattern of Tregs that might contribute BKV infection, and assessed their
prognostic value for the KTx outcomes.
Methods: We evaluated 20 KTx recipients (male:13, mean age:41±12 years, living
donor 15) in whom BKV viremia/viruria was detected at a median 12.6 (IQR, 4.6-31.2)
months after KTx. Serum and urine BKV DNA were measured by real-time PCR at
baseline, 1 and 3 months after detection of BKV viremia/viruria. Lymphocyte profile and
CD4(+)CD25(+)FoxP3(+) Tregs were measured by flow cytometry concurrently at these
time points. Graft outcomes over 8 years were examined in relation to BK viremia, viruria
levels, and lymphocyte profiles.
Results: At the time of diagnosis of BKV viremia/viruria, 17 (85%) patients
were on calcineurin inhibitor (CNI)-based triple immunosuppression. CNI was
discontinued in 9 patients, sirolimus was started in 3 of them. Mycophenolic acid was
switched to azathioprine or the dose was decreased in all patients. Reduction in overall
immunosuppression was associated with a decrease in serum and urine BKV DNA
levels. Tregs and CD8(+) T lymphocytes were significantly decreased and CD4(+) T
lymphocytes were increased during this period (Figure 1). After a median follow-up of
8.1 years (IQR, 3.3-8.5), 6 (30%) patients lost their allografts. There were no significant
differences in mean Tregs levels between patients with and without graft failure (p=0.63).
Serum and urine mean BKV DNA levels were similar between patients with and without
graft failure (p=0.38 and p=0.20, respectively).
Conclusions: Tregs may play a role in BKV infection, reduction in the overall
amount of immunosuppression is associated with improvement of BKV viremia/
viruria accompanied by a decrease in Treg levels. Future work is needed to discriminate
predictors of allograft failure in patients with BK nephropathy.

Regulatory T cell subpopulation according to the patient’s characteristics.
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Expansion and Characterization of Regulatory T Cell Populations from
Korean Kidney Transplant Recipients
Ho Sik Shin,1,2 Youngchan Park,1 Ye na Kim,1,2 Yeonsoon Jung,1,2 Hark Rim.1,2
1
Kosin University Gospel Hospital, Busan, Busan, Republic of Korea;
2
Transplantation Research Institute, Kosin University College of Medicine,
Busan, South Korea, Republic of Korea.
Background: The development of immunosuppressants has enabled remarkable
progress in kidney transplantation (KT). However, current immunosuppressants cannot
achieve induction of immune tolerance and their nonspecific immunosuppressive effects
result in many adverse effects. Regulatory T cells (Tregs) play crucial roles in controlling
allospecific immune responses. This study evaluated the distribution of Tregs and their
effects on kidney allograft function in Korean KT recipients.

Diagnosis of Early Delayed Graft Function (DGF) Using TIMP-2*IGFPB-7 Product in Transplant Recipients: Preliminary Results
Russell Leong,2,1 Cassandra Rodd,2,1 Kellyann M. Gomes,2,1
Solomiia Savedchuk,2,1 Paul S. Kellerman.2,1 1Oakland University William
Beaumont School of Medicine, Rochester, MI; 2Beaumont Health, Royal Oak, MI.
Background: DGF is acute kidney injury (AKI) defined as need for dialysis within
one week of renal transplant. AKI is defined by a change in serum creatinine (SCr),
however early recognition is limited by delay in creatinine rise. Accurate early biomarkers
may lead to prevention or treatment of established AKI. The product of two novel
biomarkers of cell cycle arrest, tissue Inhibitor of metalloproteinase-2 (TIMP-2) and
insulin-like growth factor binding protein (IGFBP-7) have shown promise in predicting
AKI. In prior studies, TIMP-2*IGFPB-7 ≤0.3 had high negative predictive value, and ≥2
high positive predictive value for AKI. Aims - 1) Investigate the early diagnostic value of
TIMP-2*IGFPB-7 for DGF; 2) Correlate TIMP-2*IGFPB-7 with long term graft function.
Methods: This is a prospective, double-blinded single center observational study
with goal enrollment of 150 transplant recipients. Urine TIMP-2*IGFBP-7 was measured
in (ng/mL)2/1000 with a commercial kit, Nephrocheck (Astute Medical, San Diego, CA)
at 4-12 hours, 48-72 hours and 72-96 hours post-transplant. SCr was measured just prior
to transplant, 1 week post-transplant, and at 1, 3, 6, 9 and 12 months post-transplant.
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Results: Thus far, 64 patient samples have been collected, 11 with DGF. Mean TIMP2*IGFPB-7 were 3.08 ± 0.63 vs 0.54 ± 0.23 (p-value <0.001) at 4-12 hours, 3.39 ± 0.93 vs
0.38 ± 0.13 at 24-48 hours (p-value <0.001), and 1.73 ± 0.76 vs 0.62 ± 0.27 (p-value =0.09)
at 72-96 hours in DGF vs non DGF patients respectively. Mean SCr at 1 week were
6.14 ± 0.71 mg/dL in DGF vs 2.13 ± 0.26 mg/dL (p-value <0.001) in non-DGF. Correlation
between peak TIMP-2*IGFPB-7 at 24-48 hours and sCr at 1, 3, 6, 9, and 12 months, was
nonsignificant.
Conclusions: These preliminary results confirm the use of TIMP-2*IGFBP product
measured by Nephrocheck in the diagnosis and prediction of DGF in the post-kidney
transplant period as early as 4-12 hours, and peaking at 24-48 hours. The non-DGF
TIMP-2*IGFBP-7 means were higher than prior reports, suggesting mild renal injury in
the peritransplant period in those patients without DGF. The current sample size is too
small and underpowered as of yet to draw conclusions on prediction of long-term renal
dysfunction.
Funding: Commercial Support - Astute Medical Inc
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Kidney Injury in Hematopoietic Stem Cell Transplant (HCT) Recipients:
Transcriptome Profiling and Development of Urinary Biomarkers
Elly Varma, Thalia Salinas, Carol Y. Li, Catherine Snopkowski,
Thangamani Muthukumar. Weill Cornell Medicine, New York, NY.
Background: In kidney biopsies of HCT recipients, thrombotic microangiopathy
with/without tubulointerstitial/microvascular inflammation suggest the possibility of
kidney being a target of graft versus host disease. We tested the hypothesis: (i) kidney
inflammation/injury in HCT recipients is immune mediated, (ii) urinary mRNA profile
may be used as a noninvasive biomarker.
Methods: (i) RNA-sequencing of native kidney from 6 HCT recipients with kidney
injury was performed. We compared the transcriptome profile to that of allograft kidney.
(ii) Urine samples from 9 HCT recipients were collected. We calculated the CTOT-04
signature score for each recipient. We compared the score to that of kidney allograft
recipients.
Results: Of the 4188 genes (26% of 16375) that were different (FDR-P<0.05)
between HCT and Normal, 2152 were shared among HCT, ACR, and AMR; 1442 were
unique to HCT (Figure 1). Shared genes revealed enrichment of innate and adaptive
immune system pathways. Urinary cell CTOT-04 signature score was higher in AKI/
tubulitis and interstitial inflammation in the native kidney and resembled ACR of kidney
allograft recipients (Figure 2).
Conclusions: In recipients of HCT: (i) kidney inflammation/injury is immune
mediated, (ii) urinary cell mRNA profiling is useful for diagnosing kidney injury
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The Role of Hyperleptinaemia and Low Values of Interleukin 10 in De
Novo Donor-Specific Antibody Production After Kidney Transplantation
Ivana Dedinska.1,2 Transplant center Martin 1Univerzita Komenskeho v
Bratislave Jesseniova lekarska fakulta v Martine, Martin, Slovakia;
2
Univerzitna nemocnica Martin, Martin, Slovakia.
Background: White adipose tissue secretes a number of peptide hormones, including
leptin, adiponectin, and several cytokines. The aim of this paper was to determine the role
of selected adipocytokines (leptin and adiponectin) and interleukins (IL-10 and IL-6) on
the development of graft rejection in protocol biopsy after kidney transplantation.
Methods: In a prospective analysis (n=104), we monitored the values of leptin,
adiponectin, IL-6, and IL-10 prior to the transplantation and in the 3rd month after the
transplantation. The protocol biopsy of the graft was performed in the 3rd month after the
transplantation. The group was divided into the following according to the biopsy result:
negative result, IFTA 1, borderline, and DSA positive.
Results: After adjusting for the differences in the baseline recipient and donor
characteristics, we identified the hyperleptinaemia baseline (HR=2.0444, P=0.0341) and
month 3 (HR=49.8043, P<0.0001) as independent risk factors for borderline changes in
the protocol biopsy. The hyperleptinaemia baseline (HR=7.4979, P=0.0071) and month
3 (HR=9.7432, P=0.0057) are independent risk factors for de novo DSA positivity. A
low value of IL-10 month 3 is a risk factor for de novo DSA positivity (HR=3.0746,
P=0.0388).
Conclusions: Higher leptin levels might play a role in rejection and de novo DSA
production. We also confirmed the influence of low values of IL-10 on the development
of de novo DSA. We assume that values of adipocytokines in context of other risk factors
can predict the immunological risk of patients after kidney transplantation.
Funding: Government Support - Non-U.S.

ROC curve. Leptin 3M and IL-10 3M for the endpoint of de novo DSA and borderline
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Diagnostic Performance of Donor-Derived Cell-Free DNA Assay
(AlloSure®) in Kidney Transplant Recipients with Graft Dysfunction:
A Single-Center Study
Muhammad S. Naseer, Ayush Singh, Neeraj Singh. Willis Knighton Medical
Center, Shreveport, LA.
Background: Circulating donor-derived cell-free DNA (dd-cf-DNA) is a noninvasive biomarker of kidney allograft injury with a high negative predictive value for
ruling out active rejection in patients with evidence of graft dysfunction. At our center, we
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